Abiopharma

🔍 RA CAPITAL MANAGEMENT, L.P. (Executive)

Company: Hemab Therapeutics Holdings, Inc. (COAG)

Report Date: 2026-05-04

Detailed Transactions and Holdings:

• Acquired 3,607,846 shares of Common Stock (Direct)
  Date: 2026-05-04 | Code: C | equity_swap_involved: 0 | shares_owned_after: 3,607,846.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Acquired 1,009,052 shares of Common Stock (Direct)
  Date: 2026-05-04 | Code: C | equity_swap_involved: 0 | shares_owned_after: 1,009,052.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Acquired 221,188 shares of Common Stock (Direct)
  Date: 2026-05-04 | Code: C | equity_swap_involved: 0 | shares_owned_after: 221,188.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Acquired 2,541,250 shares of Common Stock at $18.0 per share (Direct)
  Date: 2026-05-04 | Code: P | equity_swap_involved: 0 | shares_owned_after: 6,149,096.00 | transaction_form_type: 4 | Footnotes: F2
• Acquired 133,750 shares of Common Stock at $18.0 per share (Direct)
  Date: 2026-05-04 | Code: P | equity_swap_involved: 0 | shares_owned_after: 354,938.00 | transaction_form_type: 4 | Footnotes: F2
• Acquired 87,143 shares of Common Stock at $24.59 per share (Direct)
  Date: 2026-05-05 | Code: P | equity_swap_involved: 0 | shares_owned_after: 6,236,239.00 | transaction_form_type: 4 | Footnotes: F6, F2
• Acquired 10,268 shares of Common Stock at $25.0 per share (Direct)
  Date: 2026-05-05 | Code: P | equity_swap_involved: 0 | shares_owned_after: 6,246,507.00 | transaction_form_type: 4 | Footnotes: F2
• Acquired 14,611 shares of Common Stock at $23.77 per share (Direct)
  Date: 2026-05-06 | Code: P | equity_swap_involved: 0 | shares_owned_after: 6,261,118.00 | transaction_form_type: 4 | Footnotes: F7, F2
• Acquired 53,407 shares of Common Stock at $24.83 per share (Direct)
  Date: 2026-05-06 | Code: P | equity_swap_involved: 0 | shares_owned_after: 6,314,525.00 | transaction_form_type: 4 | Footnotes: F8, F2
• Sold 1,422,960 shares of Series A Preferred Stock (Derivative)
  Date: 2026-05-04 | Code: C | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1, F1, F1, F1, F2
• Sold 609,840 shares of Series A Preferred Stock (Derivative)
  Date: 2026-05-04 | Code: C | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1, F1, F1, F1, F2
• Sold 931,502 shares of Series B Preferred Stock (Derivative)
  Date: 2026-05-04 | Code: C | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1, F1, F1, F1, F2
• Sold 399,212 shares of Series B Preferred Stock (Derivative)
  Date: 2026-05-04 | Code: C | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1, F1, F1, F1, F2
• Sold 1,253,384 shares of Series C Preferred Stock (Derivative)
  Date: 2026-05-04 | Code: C | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1, F1, F1, F1, F2
• Sold 221,188 shares of Series C Preferred Stock (Derivative)
  Date: 2026-05-04 | Code: C | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1, F1, F1, F1, F2

Footnotes:

• F1: Each share of Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a 22-for-1 basis, and had no expiration date.
• F2: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus II Fund, L.P. (the "Nexus Fund II") and RA Capital Nexus IV Fund, L.P. (the "Nexus Fund IV"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund II, the Nexus Fund IV, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.
• F3: Held directly by the Fund.
• F4: Held directly by Nexus Fund II.
• F5: Held directly by Nexus Fund IV.
• F6: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $24.00 to $24.9994 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
• F7: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $23.495 to $24.455 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
• F8: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $24.505 to $25.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
• REMARKS: Dr. Laura Tadvalkar, a Managing Director of the Adviser, serves on the Issuer's board of directors.